Innovent Biosciences Collaborates with Chipscreen to Evaluate Chidamide in Combination with Sintilimab & IBI305 in China

 Innovent Biosciences Collaborates with Chipscreen  to Evaluate Chidamide in Combination with Sintilimab & IBI305 in China

Innovent Biosciences Collaborates with Chipscreen to Evaluate Chidamide in Combination with Sintilimab & IBI305 in China

Shots:

  • The companies collaborated to jointly assess safety and efficacy of Chipscreen’s Chidamide in combination with Innovent’s Sintilimab + IBI305 in patients with advanced colorectal carcinoma (ACC)
  • The focus of the agreement is to explore the combination in clinical applications of immune check-point inhibitor, angiogenesis inhibitor and epigenetic modulator in ACC 
  • Chidamide is a HDAC inhibitor inducing apoptosis of tumor cells, has received CFDA’s approval in Dec,2014. Sintilimab (IBI308) & IBI305 (bevacizumab, biosimilar) is an anti-PD-1Ab & an anti VEGF mAb respectively binds to PD-1 receptor & producing antitumour targeting tumour cells respectively

Click here to read full press release/ article| Ref: PRNewswire | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post